|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Desai A, Xu J, Aysola K, Qin Y, Okoli C,
Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, et al:
Epithelial ovarian cancer: An overview. World J Transl Med. 3:1–8.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roett MA and Evans P: Ovarian cancer: An
overview. Am Fam Physician. 80:609–616. 2009.PubMed/NCBI
|
|
4
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lawrie TA, Rabbie R, Thoma C and Morrison
J: Pegylated liposomal doxorubicin for first-line treatment of
epithelial ovarian cancer. Cochrane Database Syst Rev.
10:CD0104822013.PubMed/NCBI
|
|
7
|
Griffiths RW, Zee YK, Evans S, Mitchell
CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR and Hasan J: Outcomes
after multiple lines of chemotherapy for platinum-resistant
epithelial cancers of the ovary, peritoneum and fallopian tube. Int
J Gynecol Cancer. 21:58–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bowden NA: Nucleotide excision repair: Why
is it not used to predict response to platinum-based chemotherapy?
Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wijnhoven SW, Hoogervorst EM, de Waard H,
van der Horst GT and van Steeg H: Tissue specific mutagenic and
carcinogenic responses in NER defective mouse models. Mutat Res.
614:77–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gossage L and Madhusudan S: Current status
of excision repair cross complementing-group 1 (ERCC1) in cancer.
Cancer Treat Rev. 33:565–577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dabholkar M, Bostick-Bruton F, Weber C,
Bohr VA, Egwuagu C and Reed E: ERCC1 and ERCC2 expression in
malignant tissues from ovarian cancer patients. J Natl Cancer Inst.
84:1512–1517. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferry KV, Hamilton TC and Johnson SW:
Increased nucleotide excision repair in cisplatin-resistant ovarian
cancer cells: Role of ERCC1-XPF. Biochem Pharmacol. 60:1305–1313.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Steffensen KD, Waldstrøm M and Jakobsen A:
The relationship of platinum resistance and ERCC1 protein
expression in epithelial ovarian cancer. Int J Gynecol Cancer.
19:820–825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bosmuller H, Haitchi-Petnehazy S,
Webersinke G, Marschon R, Roithmeier F, Stummvoll W, Fehm T,
Klier-Richter M, Bonzheim I, et al: Intratumoral lymphocyte density
in serous ovarian carcinoma is superior to ERCC1 expression for
predicting response to platinum-based therapy. Virchows Arch.
459:183–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stadlmann S, Dirnhofer S, Güth U, Thies S
and Singer G: ERCC1-immunoexpression does not predict
platinum-resistance in ovarian cancer. Gynecol Oncol. 108:252–253.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Milovic-Kovacevic M, Srdic-Rajic T,
Radulovic S, Bjelogrlic S and Gavrilovic D: Expression of ERCC1
protein in biopsy specimen predicts survival in advanced ovarian
cancer patients treated with platinum-based chemotherapy. J BUON.
16:708–714. 2011.PubMed/NCBI
|
|
17
|
Scheil-Bertram S, Tylus-Schaaf P, du Bois
A, Harter P, Oppitz M, Ewald-Riegler N and Fisseler-Eckhoff A:
Excision repair cross-complementation group 1 protein
overexpression as a predictor of poor survival for high-grade
serous ovarian adenocarcinoma. Gynecol Oncol. 119:325–331. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Muallem MZ, Marnitz S, Richter R, Köhler
C, Sehouli J and Arsenic R: ERCC1 expression as a predictive marker
of cervical cancer treated with cisplatin-based chemoradiation.
Anticancer Res. 34:401–406. 2014.PubMed/NCBI
|
|
19
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin H and Changchien CC: Management of
relapsed/refractory epithelial ovarian cancer: Current standards
and novel approaches. Taiwan J Obstet Gynecol. 46:379–388. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Colombo N and Gore M: Treatment of
recurrent ovarian cancer relapsing 6–12 months post platinum-based
chemotherapy. Crit Rev Oncol Hematol. 64:129–138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing-group 1 Gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
|
|
23
|
Andrieux LO, Fautrel A, Bessard A,
Guillouzo A, Baffet G and Langouët S: GATA-1 is essential in
EGF-mediated induction of nucleotide excision repair activity and
ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res.
67:2114–2123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Niedernhofer LJ, Odijk H, Budzowska M, van
Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB,
Hoeijmakers JH and Kanaar R: The structure-specific endonuclease
Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced
double-strand breaks. Mol Cell Biol. 24:5776–5787. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kirschner K and Melton DW: Multiple roles
of the ERCC1-XPF endonuclease in DNA repair and resistance to
anticancer drugs. Anticancer Res. 30:3223–3232. 2010.PubMed/NCBI
|
|
26
|
Dabholkar M, Vionnet J, Bostick-Bruton F,
Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian
cancer tissue correlate with response to platinum-based
chemotherapy. J Clin Invest. 94:703–708. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vilmar A and Sorensen JB: Excision repair
cross-complementation group 1 (ERCC1) in platinum-based treatment
of non-small cell lung cancer with special emphasis on carboplatin:
A review of current literature. Lung Cancer. 64:131–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bonanno L, Favaretto A and Rosell R:
Platinum drugs and DNA repair mechanisms in lung cancer. Anticancer
Res. 34:493–501. 2014.PubMed/NCBI
|
|
29
|
Metzger R, Bollschweiler E, Holscher AH
and Warnecke-Eberz U: ERCC1: Impact in multimodality treatment of
upper gastrointestinal cancer. Future Oncol. 6:1735–1749. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li FY, Ren XB, Xie XY and Zhang J:
Meta-analysis of excision repair cross-complementation group 1
(ERCC1) association with response to platinum-based chemotherapy in
ovarian cancer. Asian Pac J Cancer Prev. 14:7203–7206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao D, Zhang W, Li XG, Wang XB, Li M, Li
YF, Tian HM, Song PP, Liu J, Chang QY and Wu LY: The mRNA
expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their
relationship with clinical chemosensitivity in primary epithelial
ovarian cancer. Zhonghua Zhong Liu Za Zhi. 34:196–200. 2012.(In
Chinese). PubMed/NCBI
|
|
32
|
Rubatt JM, Darcy KM, Tian C, Muggia F,
Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer
M and Krivak TC: Pre-treatment tumor expression of ERCC1 in women
with advanced stage epithelial ovarian cancer is not predictive of
clinical outcomes: A gynecologic oncology group study. Gynecol
Oncol. 125:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kiyohara C and Yoshimasu K: Genetic
polymorphisms in the nucleotide excision repair pathway and lung
cancer risk: A meta-analysis. Int J Med Sci. 4:59–71. 2007.
View Article : Google Scholar : PubMed/NCBI
|
